Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Telix-Pharmaceuticals

More Like This

PR Newswire associated0

Positive Topline Results from Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer Presented at SABCS

PR Newswire associated0

First Patient Dosed in Italian Named Patient (Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent

PR Newswire associated0

Telix Submits Biologics License Application (BLA) for TLX250-CDx (Zircaix™) for Imaging of Kidney Cancer

PR Newswire associated0

Telix Featured in 13 Abstracts at the Annual Congress of the European Association of Nuclear Medicine (EANM)

PR Newswire associated0

First Patient Dosed in European Named Patient (Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent

PR Newswire associated0

Telix Completes TLX250-CDx (Zircaix®) BLA Submission for Kidney Cancer Imaging

PR Newswire associated0

Telix Submits NDA for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent

PR Newswire associated0

'Highly Accurate': Telix's Phase III ZIRCON Trial for Kidney Cancer Imaging Published in The Lancet Oncology